MindMed has announced the dosing of the first patient in its phase 3 Voyage study of MM120 ODT, a pharmaceutically optimised form of lysergide D-tartrate (LSD) for treating Generalised Anxiety ...

Berlin’s Diagnostisch Therapeutisches Zentrum (DTZ) has become the first in the world to treat a patient using Elekta Evo, an ...

Global biotechnology leader CSL has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for ...

Beckley Psytech has announced positive topline results from its phase 2a study of ELE-101, a synthetic intravenous (IV) ...

Patients don’t take their medicines because they don’t want to Debra is late getting up for work again. In her heart of ...

Bayer’s initiative reflects a broader effort to address the high unmet medical need in oncology. The trial’s success could ...

Minoryx Therapeutics and Neuraxpharm Group have announced that leriglitazone has met the primary endpoint in the NEXUS trial ...